Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA)

NCT02095548 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Osteoarthritis

Interventions

DRUG: SM04690, 0.03mg/2mL
DRUG: SM04690, 0.07mg/2mL
DRUG: SM04690, 0.23mg/2mL
DRUG: Placebo

Sponsor

Biosplice Therapeutics, Inc.